Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Genentech (NYSE:DNA) formerly known as (NYSE:GNE)

An SI Board Since July 1999

Posts	SubjectMarks	Bans	Symbol
250	46	0	DNA

Emcee: esecurities(tm)	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
125	>>Supreme Court reverses MedImmune dismissal High court disagrees with fed	tuck	-	1/9/2007
124	LOL..looks like the brain had a bit of a spelling/pronouciation seizure although	zeta1961	-	1/6/2007
123	>>Genentech is not only an A+ biotech but also deserves kudos for symantec	tuck	-	1/6/2007
122	Something is very fishy..there was an ELN analyst who made this statement during	zeta1961	-	1/5/2007
121	All the media fuss aside, the takeaway is that the fate of Omnitarg depends on t	tuck	-	1/5/2007
120	Thanks, a good review of "pharmaspeak." DNA was to make a "go/no	tuck	-	1/5/2007
119	BOSTON, Jan 5 (Reuters) - An ovarian cancer drug under development by Genentech	nigel bates	-	1/5/2007
118	>>Genentech Announces Positive Results From a Randomized Phase II Study of	tuck	-	1/4/2007
117	FDA Approves Herceptin for the Adjuvant Treatment of HER2-Positive Node-Positive	zeta1961	-	11/16/2006
116	Merrill Updating oncology, Lucentis product models We are updating our oncology	tom pope	-	11/8/2006
115	<b> Pennsylvania Doc Says Entitled to Lucentis Revenues </b> <i&	DewDiligence_on_SI	-	10/19/2006
114	Nice recap. Off label use of Avastin hasn't hurt Lucentis sales, something	technetium	-	10/11/2006
113	Genentech's Profit Climbs 58% Amid Pressure to Pare Drug Prices [WSJ] By DA	Doc Bones	-	10/11/2006
112	It is now trading, down over 1.70, did see some trades down 3. EDIT - it's	tom pope	-	10/10/2006
111	I don't see any AH trades, but that doesn't seem to me to be the sort of	tom pope	-	10/10/2006
110	>>Genentech Announces Third Quarter 2006 Results Tuesday October 10, 4:02	tuck	-	10/10/2006
109	Merrill: Avastin vs. Lucentis is No Lay Up Due to Safety & Costs: The New E	tom pope	-	10/6/2006
108	U.S. to Hold Head-to-Head Trial of 2 Genentech Drugs to Treat Eye Ailment [NYT]	Doc Bones	-	10/6/2006
107	Weird. Yesterday DNA was a buy at ML, today I get this when I pull it up: <i	tom pope	-	10/5/2006
106	Here's a slightly fuller discussion of the NDC data: NDC Data Restatement S	tom pope	-	10/4/2006
105	Merrill - the reason for this morning's decline, I guess: <i>Genentec	tom pope	-	10/4/2006
104	Why did MEGA hedge fund SAC Capital Advisors recently offload ~90% of their Gene	Henrik	-	10/3/2006
103	Calling on Genentech MONDAY, OCTOBER 2, 2006 THE STRIKING PRICE By KOPI	Doc Bones	-	9/30/2006
102	The gift that keeps giving.. FDA Approves Two New Indications for Rituxan in P	zeta1961	-	9/29/2006
101	Merrill: This Focus 1 Announcement is sent to you at your request only when the	tom pope	-	9/14/2006

Go to reply# or date (mm/dd/yy):